Edition:
United Kingdom

GSK exercises option over SPEAR T-cell therapy program targeting NY-ESO


Thursday, 7 Sep 2017 

Sept 7 (Reuters) - Adaptimmune Therapeutics Plc :Adaptimmune Therapeutics Plc - ‍GSK exercises option over SPEAR T-cell therapy program targeting NY-ESO​.Adaptimmune Therapeutics Plc - ‍Adaptimmune will receive up to £48 million ($61 million) from GSK over course of transition period​.Adaptimmune Therapeutics Plc - ‍anticipate transition of NY-ESO to GSK to be completed over coming months​. 

Company Quote

3.44
0.09 +2.69%
18 Jul 2019